FOR US HEALTHCARE PROFESSIONALS ONLY
Recommend the FIRST and ONLY treatment with 6 months of symptom control per dose1*
Evaluated vs INVEGA TRINZA® and in an open-label extension trial1-3
On this page:
Safety was similar to that of INVEGA TRINZA® and evaluated long term in an open-label extension trial1,3
Transition patients to INVEGA HAFYERA® and other dosing considerations
A step-by-step guide for administering INVEGA HAFYERA®
In a survey of adults on daily orals for schizophrenia
94%
said they would prefer to move beyond a monthly injection to a 3- or 6-month injection, vs remaining on a once-monthly option.4†
*Before transitioning to INVEGA HAFYERA®, patients must be adequately treated with either INVEGA SUSTENNA® for at least 4 months (with the last 2 doses being 156 mg or 234 mg), or INVEGA TRINZA® for at least one 3-month injection cycle (at doses of 546 mg or 819 mg).1
†Based on results from a survey of randomly selected adult patients with schizophrenia (N=200). A subgroup of patients were daily oral antipsychotic users who were open to an HCP recommendation of any LAI option (n=140), and among those patients, 94% (n=132/140) agreed to move from a 1-month option to a 3- or 6-month option.4
References: 1. INVEGA HAFYERA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. Najarian D, Sanga P, Wang S, et al. A randomized, double-blind, multicenter, noninferiority study comparing paliperidone palmitate 6-month versus the 3-month long-acting injectable in patients with schizophrenia. Int J Neuropsychopharmacol. 2022;25(3):238-251. 3. Najarian D, Turkoz I, Knight RK, et al. Long-term efficacy and safety of paliperidone 6-month formulation: an open-label 2-year extension of a 1-year double-blind study in adult participants with schizophrenia. Int J Neuropsychopharmacol. 2023;26(8):537-544. 4. Data on file. Janssen Pharmaceuticals, Inc.